New targeted drug trial for tough-to-treat lung cancer
Disease control
Terminated
This study aimed to see if a new drug called poziotinib works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation and has worsened after prior treatments. It directly compared how long each treat…
Phase: PHASE3 • Sponsor: Spectrum Pharmaceuticals, Inc • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC